{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:22:51Z","timestamp":1760296971590},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,6,20]],"date-time":"2003-06-20T00:00:00Z","timestamp":1056067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autologous stem cell transplantation (ASCT) has enabled the use of high\u2010dose alkylating agents either as a single agent or in combination with other cytotoxic agents and\/or total body irradiation (TBI) for the treatment of multiple myeloma. Despite improved complete remission rates, relapse and regimen\u2010related toxicities remain challenging. In an effort to increase event\u2010free survival and decrease the high incidence of regimen\u2010related toxicity, we have studied the use of etoposide in combination with reduced\u2010dose busulfan and cyclophosphamide as a conditioning regimen for ASCT in a group of 26 patients with advanced multiple myeloma. Median follow\u2010up for the group was 30 months. There was no early treatment\u2010related mortality. The main toxicity was mucositis. Otherwise, there was 1 case of reversible, clinically diagnosed hepatic veno\u2010occlusive disease. Post\u2010engraftment, 10 patients (38%) achieved CR, 15 (58%) patients achieved PR or SD, and 1 patient developed progressive disease (4%). Five patients in PR and 1 with progressive disease before transplant attained a CR post\u2010transplant. The median times for event\u2010free survival and overall survival after transplantation were 24 and 43 months, respectively. In conclusion, conditioning with busulfan, cyclophosphamide, and etoposide followed by ASCT is a safe regimen with comparable effectiveness to other previously used preparative regimens, thus providing another approach of non\u2010TBI containing high\u2010dose chemotherapy for patients with multiple myeloma. Am. J. Hematol. 73:169\u2013175, 2003. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.10342","type":"journal-article","created":{"date-parts":[[2003,6,23]],"date-time":"2003-06-23T10:15:21Z","timestamp":1056363321000},"page":"169-175","source":"Crossref","is-referenced-by-count":22,"title":["Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma"],"prefix":"10.1002","volume":"73","author":[{"given":"Christopher R.","family":"Cogle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan S.","family":"Moreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen L.","family":"Leather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna J.","family":"Finiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahab A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay S.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,6,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.V73.4.865.865","article-title":"Plasma cell myeloma: new biological insights and advances in therapy","volume":"73","author":"Barlogie B","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402173300709"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.334"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198302103080604"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.789"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702622"},{"issue":"11","key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V85.11.3077.bloodjournal85113077","article-title":"Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on Autologous Transplantation in Multiple Myeloma","volume":"85","author":"Harousseau J","year":"1995","journal-title":"Blood"},{"issue":"2","key":"e_1_2_1_10_2","first-page":"140","article-title":"Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation","volume":"13","author":"Bjorkstrand B","year":"1995","journal-title":"Stem Cells"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01979.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3131"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.55.401k04_55_65"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00795.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90739-0"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb06890.x"},{"issue":"10","key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1200\/JCO.1991.9.10.1880","article-title":"Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy","volume":"9","author":"Phillips G","year":"1991","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_18_2","first-page":"131","article-title":"Phase I\u2013II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma","volume":"14","author":"Schiller G","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1200\/JCO.1996.14.5.1447","article-title":"High\u2010dose therapy followed by autologous hematopoietic stem\u2010cell infusion for patients with multiple myeloma","volume":"14","author":"Bensinger W","year":"1996","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198508000-00011"},{"key":"e_1_2_1_21_2","first-page":"265","article-title":"High\u2010dose cyclophosphamide, BCNU and VP\u201016 with autologous blood stem cell support for refractory multiple myeloma","volume":"5","author":"Ventura G","year":"1990","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.V82.7.2005.2005","article-title":"High\u2010dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients","volume":"82","author":"Fermand J","year":"1993","journal-title":"Blood"},{"issue":"3","key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.1994.12.3.503","article-title":"High\u2010dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high\u2010risk multiple myeloma","volume":"12","author":"Gianni A","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19961215)78:12<2502::AID-CNCR9>3.0.CO;2-L"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-001-0413-8"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702598"},{"issue":"12","key":"e_1_2_1_27_2","first-page":"2671","article-title":"High\u2010dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission","volume":"3","author":"Zander AR","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"3","key":"e_1_2_1_28_2","first-page":"361","article-title":"Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation","volume":"15","author":"Crilley P","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90224-0"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703698"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.1999.0015"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05307.x"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702668"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.764"},{"issue":"3","key":"e_1_2_1_38_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High\u2010dose chemotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie B","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701763"},{"issue":"8","key":"e_1_2_1_40_2","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V82.8.2324.bloodjournal8282324","article-title":"Thiotepa, busulfan, cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high\u2010risk multiple myeloma","volume":"82","author":"Dimopoulos M","year":"1993","journal-title":"Blood"},{"issue":"4","key":"e_1_2_1_41_2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1200\/JCO.1994.12.4.759","article-title":"High\u2010dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma","volume":"12","author":"Cunningham D","year":"1994","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.10342","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.10342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:39:36Z","timestamp":1700242776000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.10342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,20]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1002\/ajh.10342"],"URL":"https:\/\/doi.org\/10.1002\/ajh.10342","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,20]]}}}